Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase / metabolism*
  • Antineoplastic Agents / pharmacology
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Cell-Free Nucleic Acids / genetics
  • Crizotinib / pharmacology*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Gene Amplification*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Middle Aged
  • Neoplastic Cells, Circulating / metabolism
  • Neoplastic Cells, Circulating / pathology
  • Prognosis
  • Proto-Oncogene Proteins c-met / genetics*

Substances

  • Antineoplastic Agents
  • Cell-Free Nucleic Acids
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • MET protein, human
  • Proto-Oncogene Proteins c-met